Cediranib
Acute Leukemias of Ambiguous Lineage
National Cancer Institute (NCI)Small moleculePhase 1Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Acute Leukemias of Ambiguous Lineage cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
L-Ofloxacin Children's Oncology Group | Phase 3 | BB |
Entinostat National Cancer Institute (NCI) | Phase 1 | CC |
mk-2206 National Cancer Institute (NCI) | Phase 1 | CC |
Inotuzumab Ozogamicin SWOG Cancer Research Network | Phase 1 | CC |
Dexrazoxane National Cancer Institute (NCI) | Phase 1 | CC |
(+)-VINCRISTINE National Cancer Institute (NCI) | Phase 1 | CC |
Inno-206 National Cancer Institute (NCI) | Phase 1 | CC |
gx15-070ms National Cancer Institute (NCI) | Phase 1 | CC |
Same molecule, other indications
Cediranib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →